Nxera Pharma Co Ltd (SOLTF)
9.304
0.00 (0.00%)
USD |
OTCM |
Apr 30, 16:00
Nxera Pharma Enterprise Value: 972.08M for April 29, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 29, 2024 | 972.08M |
| April 26, 2024 | 972.08M |
| April 25, 2024 | 1.010B |
| April 24, 2024 | 1.010B |
| April 23, 2024 | 1.010B |
| April 22, 2024 | 1.010B |
| April 19, 2024 | 1.010B |
| April 18, 2024 | 1.010B |
| April 17, 2024 | 1.010B |
| April 16, 2024 | 1.010B |
| April 15, 2024 | 1.074B |
| April 12, 2024 | 1.074B |
| April 11, 2024 | 1.074B |
| April 10, 2024 | 1.074B |
| April 09, 2024 | 1.074B |
| April 08, 2024 | 1.074B |
| April 05, 2024 | 1.034B |
| April 04, 2024 | 1.034B |
| April 03, 2024 | 1.034B |
| April 02, 2024 | 1.106B |
| April 01, 2024 | 1.106B |
| March 28, 2024 | 1.082B |
| March 27, 2024 | 1.082B |
| March 26, 2024 | 1.082B |
| March 25, 2024 | 1.082B |
| Date | Value |
|---|---|
| March 22, 2024 | 1.082B |
| March 21, 2024 | 1.082B |
| March 20, 2024 | 1.082B |
| March 19, 2024 | 1.082B |
| March 18, 2024 | 1.082B |
| March 15, 2024 | 1.101B |
| March 14, 2024 | 1.101B |
| March 13, 2024 | 1.101B |
| March 12, 2024 | 1.341B |
| March 11, 2024 | 1.341B |
| March 08, 2024 | 1.024B |
| March 07, 2024 | 1.024B |
| March 06, 2024 | 1.024B |
| March 05, 2024 | 1.024B |
| March 04, 2024 | 1.024B |
| March 01, 2024 | 1.026B |
| February 29, 2024 | 1.026B |
| February 28, 2024 | 920.20M |
| February 27, 2024 | 920.20M |
| February 26, 2024 | 920.20M |
| February 23, 2024 | 920.20M |
| February 22, 2024 | 920.20M |
| February 21, 2024 | 920.20M |
| February 20, 2024 | 920.20M |
| February 16, 2024 | 920.20M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
429.47M
Minimum
May 12 2022
1.713B
Maximum
Jul 29 2019
1.016B
Average
1.010B
Median
Apr 16 2024
Enterprise Value Benchmarks
| Takeda Pharmaceutical Co Ltd | 71.87B |
| PeptiDream Inc | 1.250B |
| Stemcell Holdings Inc | -- |
| Healios KK | 73.17M |
| AnGes Inc | 37.97M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.409M |
| Revenue (Quarterly) | 49.39M |
| Total Expenses (Quarterly) | 59.78M |
| EPS Diluted (Quarterly) | -0.0144 |
| Gross Profit Margin (Quarterly) | 76.00% |
| Profit Margin (Quarterly) | -2.85% |
| Earnings Yield | -6.63% |
| Normalized Earnings Yield | -6.627 |